Can anticoagulant treatment be tailored with biomarkers in patients with venous thromboembolism?
Kamphuisen
P W
PW
Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. p.w.kamphuisen@amc.uva.nl
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D005169:Factor VIII / Q000378:metabolism; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006470:Hemorrhage / Q000209:etiology*; D006801:Humans; D012307:Risk Factors; D055502:Secondary Prevention; D013923:Thromboembolism / Q000097:blood / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000097:blood / Q000517:prevention & control*; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use*
D000925:Anticoagulants; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D014859:Warfarin; C078147:F8 protein, human; D005169:Factor VIII